In order to develop a novel (99m) Tc-labeled folate receptor (FR) imaging agent, a dithiocarbamate derivative, pteroyl-lys-DTC, was synthesized and radiolabeled with (99m) Tc through the [(99m) TcN](2+) intermediate. The radiochemical purity of the corresponding (99m) Tc-complex, (99m) TcN-pteroyl-lys-DTC, was over 95% as measured by reversed-phase HPLC. The (99m) TcN complex was stable under physiological conditions. (99m) TcN-pteroyl-lys-DTC exhibited specific FR binding in FR-positive KB cells in vitro. The biodistribution in tumor-bearing mice showed that the (99m) TcN-labeled radiotracer had good uptake (3.56 ± 0.09%ID/g at 2 h postinjection) in FR-positive KB tumors, as well as in the kidneys (30.34 ± 3.53%ID/g at 2 h postinjection). After coinjection with excess folic acid, the uptake in tumor and kidneys was significantly blocked. The results indicated that (99m) TcN-pteroyl-lys-DTC was able to target the FR-positive tumor cells and tissues specifically both in vitro and in vivo.